diallyl imidodicarbonate | 129220-90-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: diallyl imidodicarbonate
• 英文别名: prop-2-en-1-yl N-[(prop-2-en-1-yloxy)carbonyl]carbamate；prop-2-enyl N-prop-2-enoxycarbonylcarbamate
• CAS: 129220-90-2
• 化学式: C₈H₁₁NO₄
• 分子量: 185.18
• InChiKey: JYANLXRJYRTZRC-UHFFFAOYSA-N

物化性质

• 沸点：
  256.7±29.0 °C(Predicted)
• 密度：
  1.111±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  diallyl imidodicarbonate 生成 allyl allylcarbamate
  参考文献：
  名称：

  Allyl-n-allylcarbamate; n-allylcarbamates

  摘要：

  公开号：

  US02819292A1
• 作为产物：
  描述：

  氯甲酸烯丙酯 在 potassium cyanate 、 烯丙醇 作用下， 反应 2.0h， 以50%的产率得到diallyl imidodicarbonate
  参考文献：
  名称：

  Lobatamides的光活化无环类似物的合成

  摘要：

  洛巴胺和相关的水杨酸酯烯酰胺天然产物是有效的哺乳动物V-ATPase抑制剂。为了探究洛巴酰胺与哺乳动物V-ATPase结合的细节，已经制备了三种带有二苯甲酮光亲和标记的可光活化类似物。这些类似物是在简化的无环类似物2的基础上设计的。在这些衍生物的合成途径中采用了酰胺侧链的后期安装和串联脱羧/酰胺化。简化的类似物2对牛网格蛋白包被的囊泡V-ATPase（10 nM）表现出强烈的抑制作用。类似物3 - 5，以选择用于将来光亲和标记研究的合适候选也评价抑制牛V-ATP酶的。

  DOI：

  10.1021/jo0477751
• 作为试剂：
  描述：

  (4S,5R,6S)-6-((R)-1-Hydroxy-ethyl)-3-hydroxymethyl-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid allyl ester 在 diallyl imidodicarbonate 作用下， 生成 (4S,5R,6S)-3-Aminomethyl-6-((R)-1-hydroxy-ethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid allyl ester
  参考文献：
  名称：

  Synthesis and antibacterial activity of lipophilic carbapenems with anti-MRSA activity

  摘要：

  A series of sulphur-linked and carbon-linked lipophilic carbapenems has been prepared and evaluated for antibacterial activity in vitro and in vivo and for affinity for PBP2' of Staphylococcus aureus. Potent activity in vitro against methicillin-resistant S. aureus and methicillin-resistant coagulase negative staphylococci was observed despite IC50 values for PBP2' being higher than the MIC. Copyright (C) 1996 Elsevier Science Ltd.

  DOI：

  10.1016/0960-894x(96)00450-7

文献信息

• [EN] SUBSTITUTED 4-ALKYL- AND 4-ALKANOYL-PIPERIDINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS<br/>[FR] DERIVES DE 4-ALKYL- ET 4-ALKANOYL-PIPERIDINE SUBSTITUES ET UTILISATION DE CEUX-CI COMME ANTAGONISTES DES NEUROKININES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005097774A1

  公开（公告）日：2005-10-20

  The invention concerns substituted 4-alkyl- and 4-alkanoyl-piperidine derivatives having neurokinin antagonistic activity, in particular NK1 antagonistic activity and a combined NK1/NK3 antagonistic activity, compositions comprising them and their use as a medicine, in particular for the treatment and/or prophylaxis of schizophrenia, emesis, anxiety and depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pre-eclampsia, nociception, pain, in particular visceral and neuropathic pain, pancreatitis, neurogenic inflammation, asthma, chronic obstructive pulmonary disease (COPD) and micturition disorders such as urinary incontinence. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.

  该发明涉及具有神经激肽拮抗活性的取代的4-烷基和4-烷酰基哌啶衍生物，特别是NK1拮抗活性和联合NK1/NK3拮抗活性，包含它们的组合物以及它们作为药物的用途，特别是用于治疗和/或预防精神分裂症、恶心、焦虑和抑郁症、肠易激综合征（IBS）、昼夜节律紊乱、子痫前期、疼痛感知、疼痛，特别是内脏和神经病理性疼痛、胰腺炎、神经源性炎症、哮喘、慢性阻塞性肺病（COPD）和排尿障碍，如尿失禁。根据该发明的化合物可以用一般式（I）表示，并且还包括其药学上可接受的酸性或碱性加盐物，其立体化学异构体形式，其N-氧化物形式和其前药，其中所有取代基的定义如权利要求1中所述。
• [EN] SUBSTITUTED 1-PIPERIDIN-4-YL-4-AZETIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS<br/>[FR] DERIVES SUBSTITUES DE 1-PIPERIDINE-4-YL-4-AZETIDINE-3-YL-PIPERAZINE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DE LA NEUROKININE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2004056800A1

  公开（公告）日：2004-07-08

  The invention concerns substituted 1-piperidin-4-yl-4-azefdin-3-yl-piperazine having neurokinin antagonistic activity, in particular NK1 and NK1/NK3- antagonistic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment of schizophrenia, emesis, anxiety, depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pain, neurogenic inflammation, asthma, micturition disorders such as urinary incontinence and nociception. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1. In view of their capability to antagonize the actions of tachykinins by blocking the neurokinin receptors, and in particular antagonizing the actions of substance P by blocking the NK receptors, the compounds according to the invention are useful as a medicine, in particular in the prophylactic and therapeutic treatment of tachykininmediated conditions, such as, for instance CNS disorders, in particular depression, anxiety disorders, stress-related disorders, sleep disorders, cognitive disorders, personality disorders, schizoaffective disorders, eating disorders, neurodegenerative diseases, addiction disorders, mood disorders, sexual dysfunction, pain and other CNSrelated conditions ; inflammation ; allergic disorders ; emesis ; gastrointestinal disorders, in particular irritable bowel syndrome (IBS); skin disorders ; vasospastic diseases ; fibrosing and collagen diseases ; disorders related to immune enhancement or suppression and rheumatic diseases and body weight control.

  本发明涉及具有神经激肽拮抗活性的取代1-哌啶-4-基-4-氮杂二氢-3-基-哌嗪，特别是NK1和NK1/NK3-拮抗活性，它们的制备，包含它们的组合物以及它们作为药物的用途，特别是用于治疗精神分裂症、呕吐、焦虑、抑郁、肠易激综合征（IBS）、昼夜节律紊乱、疼痛、神经源性炎症、哮喘、排尿障碍如尿失禁和疼痛感知。根据本发明，这些化合物可以用一般式（I）表示，并且还包括其药学上可接受的酸或碱盐、立体化异构体、N-氧化物形式和前药形式，其中所有取代基的定义如权利要求1所述。由于这些化合物具有通过阻断神经激肽受体拮抗激肽的作用，特别是通过阻断NK受体拮抗P物质的作用的能力，根据本发明的化合物可用作药物，特别是在预防和治疗神经激肽介导的疾病方面，例如中枢神经系统疾病，特别是抑郁症、焦虑症、与压力相关的疾病、睡眠障碍、认知障碍、人格障碍、分裂情感障碍、进食障碍、神经退行性疾病、成瘾障碍、情绪障碍、性功能障碍、疼痛和其他中枢神经系统相关疾病；炎症；过敏性疾病；呕吐；胃肠道疾病，特别是肠易激综合征（IBS）；皮肤疾病；血管痉挛性疾病；纤维化和胶原疾病；与免疫增强或抑制和风湿性疾病以及体重控制相关的疾病。
• [EN] SUBSTITUTED 1,4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS<br/>[FR] DERIVES 1,4-DI-PIPERIDIN-4-YL-PIPERAZINES SUBSTITUES EN 1,4 ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DES NEUROKININES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2004033428A1

  公开（公告）日：2004-04-22

  The invention concerns substituted 1,4-di-piperidin-4-yl-piperazine derivatives having neurokinin antagonistic activity, in particular NK1 antagonistic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment of emesis, anxiety, depression, pain, pancreatitis and IBS. The compounds according to the invention can be represented by general Formula (I), and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1. In view of their capability to antagonize the actions of neurokinins by blocking the neurokinin receptors, and in particular antagonizing the actions of substance P by blocking the NK1 receptor, the compounds according to the invention are useful as a medicine, in particular in the prophylactic and therapeutic treatment of neurokinin-mediated conditions, such as, for instance CNS disorders, in particular depression, anxiety disorders, stress-related disorders, sleep disorders, cognitive disorders, personality disorders, schizoaffective disorders, eating disorders, neurodegenerative diseases, addiction disorders, mood disorders, sexual dysfunction, pain and other CNS-related conditions; inflammation; allergic disorders; emesis; gastrointestinal disorders, in particular irritable bowel syndrome (IBS); skin disorders; vasospastic diseases; fibrosing and collagen diseases; disorders related to immune enhancement or suppression and rheumatic diseases and body weight control.

  该发明涉及具有神经激肽拮抗活性的替代1,4-二哌啶-4-基哌嗪衍生物，特别是NK1拮抗活性，它们的制备，包含它们的组合物以及它们作为药物的用途，特别是用于治疗呕吐、焦虑、抑郁、疼痛、胰腺炎和肠易激综合征。根据该发明的化合物可以用一般公式（I）表示，并且还包括其药用可接受的酸或碱盐，其立体化学异构体形式，其N-氧化物形式以及其前药，其中所有取代基的定义如权利要求书1所述。鉴于它们通过阻断神经激肽受体来拮抗神经激肽的作用，特别是通过阻断NK1受体来拮抗P物质的作用，根据该发明的化合物可用作药物，特别是在预防和治疗神经激肽介导的情况下，如中枢神经系统疾病，特别是抑郁症、焦虑症、与压力有关的疾病、睡眠障碍、认知障碍、人格障碍、分裂情感障碍、进食障碍、神经退行性疾病、成瘾障碍、情绪障碍、性功能障碍、疼痛和其他中枢神经系统相关疾病；炎症；过敏性疾病；呕吐；胃肠道疾病，特别是肠易激综合征（IBS）；皮肤疾病；血管痉挛性疾病；纤维化和胶原疾病；与免疫增强或抑制以及风湿疾病和体重控制相关的疾病。
• Stereoselective Synthesis of Novel anti-MRSA Tricyclic Carbapenems (Trinems)
  作者：Osamu Kanno、Isao Kawamoto

  DOI：10.1016/s0040-4020(00)00413-0

  日期：2000.7

  (4S)-Hydroxymethyltrinem 3 was prepared via stereoselective aldol-type reaction with optically pure (R)-2-t-butyldimethylsilyloxymethylcyclohexanone ((R)-16). (4S)-Hydroxymethyltrinem 3 was converted into various kinds of trinem derivatives with anti-MRSA activity by using the Mitsunobu reaction. (C) 2000 Elsevier Science Ltd. All rights reserved.

  (4S)-羟甲基三烯甲酸3是通过使用光学纯的（R）-2-叔丁基二甲基硅氧基甲基环己酮（（R）-16）进行的立体选择性醛式反应制备的。将（4S）-羟甲基三烯甲酸3通过使用Mitsunobu反应转化为多种具有抗MRSA活性的三烯甲酸衍生物。©2000 Elsevier Science Ltd. 保留所有权利。
• Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain
  申请人：Cid-Nunez Jose Maria

  公开号：US20080262076A1

  公开（公告）日：2008-10-23

  This invention concerns novel substituted tetracyclic tetrahydrofuran derivatives containing a cyclic amine side chain with binding affinities towards dopamine receptors, in particular dopamine D 2 receptors, towards serotonin receptors, in particular 5-HT 2A and 5-HT 2C receptors, and pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also a pharmaceutically acceptable acid or base addition salt thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein all substituents are defined as in Claim 1.

  本发明涉及一种新型取代四环四氢呋喃衍生物，其含有一个环状胺侧链，具有结合多巴胺受体的亲和力，特别是多巴胺D2受体，对5-HT2A和5-HT2C受体的亲和力，以及包含根据本发明的化合物的制药组合物，其用作药物，特别是用于预防和/或治疗一系列精神和神经疾病，特别是某些精神病、心血管和胃动力紊乱，并提供其生产过程。根据本发明的化合物可以用一般式（I）表示，并包括其药学上可接受的酸或碱盐、N-氧化物形式或季铵盐，其中所有取代基在权利要求书1中定义。